TIBSOVO® (ivosidenib tablets)
Treatment for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) & cholangiocarcinoma (CCA). See Full Prescribing Information & Boxed Warning.
Ivosidenib - Wikipedia
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. [4] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer.
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma
On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic...
Ivosidenib - NCI - National Cancer Institute
Ivosidenib works by blocking an abnormal enzyme that some cancer cells with specific changes in the IDH-1 gene make. Blocking the abnormal enzyme may make cancer cells differentiate to become more like normal cells and grow more slowly.
Tibsovo: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 20, 2018 · Tibsovo (ivosidenib) is used to treat acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes in adult patients who have an isocitrate dehydrogenase-1 (IDH1) genetic mutation as detected by an FDA-approved test.
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid …
Apr 20, 2022 · Ivosidenib — a first-in-class, oral, potent, targeted small-molecule inhibitor of mutant IDH1 — has shown clinical activity as a single agent in studies involving patients with hematologic and ...
FDA Approves New Therapy for Rare Form of Blood Cancers Called ...
The FDA approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with an isocitrate dehydrogenase-1 mutation.
FDA approves ivosidenib for myelodysplastic syndromes
On October 24, 2023, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS)...
TIBSOVO® (ivosidenib tablets), for oral use Initial U.S. Approval: 2018. WARNING: DIFFERENTIATION SYNDROME IN AML. See full prescribing information for complete boxed warning. Patients treated...
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or ...
Jun 2, 2018 · Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. Methods. We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1...